This market research report presents a detailed segmentation of the global hypertension drugs market by type (systemic hypertension drugs and pulmonary hypertension drugs) and by geography (Americas, APAC, and EMEA). The key vendors in the market are Novartis, Daiichi Sankyo, Actelion Pharmaceuticals, Boehringer Ingelheim, Sanofi, and AstraZeneca.
Technavio’s market research analysts estimate the global hypertension drugs market to decline at a CAGR of around 1% between 2016 and 2020. The reasons for the market decline are the patent expiries of major blockbuster drugs; however, to offset this decline, market vendors are coming up with fixed-dose combinations and are expected to launch new formulations over the next four years. The Americas is the leading region in the hypertension drugs market, occupying around 44% of the overall market share. The launch of new disease-modifying therapies is expected to boost this region’s growth in the coming years.
The new market research report from Technavio provides a breakdown and analysis of the hypertension drugs segments by technology.
“The market will go through considerable changes owing to the growing awareness about hypertension and its treatment options. Enhanced patient awareness results in an early diagnosis of the disease followed by treatment. For instance, the National Heart, Lung, and Blood Institute of National Institutes of Health launched the High Blood Pressure Education program which is a cooperative effort among professionals, voluntary health agencies, and state health departments with a goal to cut down death and disability related to hypertension through several professional programs, patient interaction, and public education,” says Barath Palada, Lead Analyst, Pharma, Technavio Research
The systemic hypertension drugs segment occupies the largest share in the hypertension drugs market, accounting for 87% of the total market. However, the market segment is expected to witness a decline in the forecast period because of patent expiries of drugs, followed by generic erosion. The systemic hypertension drugs market is expected to reach more than USD 27 billion by the end of 2020.
The key vendors in the global hypertension drugs market include Novartis, Daiichi Sankyo, Actelion Pharmaceuticals, Boehringer Ingelheim, Sanofi, and AstraZeneca. This market is high consolidated due to the presence of a few well-established vendors. At present, the market is declining because of the increased use of generic drugs. Therefore, companies are investing heavily in the development of new medicines for the treatment of hypertension.
A more detailed analysis is available in the Technavio report, Global Hypertension Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
